Patents by Inventor Meir Strahilevitz

Meir Strahilevitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7166295
    Abstract: Methods and reagents for improved treatment and diagnostic imaging, particularly of cancer. The methods and reagents utilize specific targeting of treatment and imaging ligands to the targeted tumor, or specific organ or tissue, in association with extracorporeal affinity adsorption of the targeting ligand. The targeted species include antibodies as well as other peptides with specific affinity to the targeted tumor organ or tissue. Included are hybrid targeting molecules, such as hybrid F(ab?)2, with one binding site specific for the target and the other binding site specific for the targeted treatment or visualization ligand. The affinity adsorption devices may include adsorbents specific to one or more of the components of the targeting molecule-targeted ligand moiety.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: January 23, 2007
    Inventor: Meir Strahilevitz
  • Publication number: 20050271653
    Abstract: Methods and devices for improved targeting to a site in an organism, particularly to a tumor target site and for extracorporeal affinity adsorption, particularly in the treatment of cancer, atherosclerosis, including coronary artery disease, unstable angina, other acute ischemic syndromes and idiopathic dilated cardiac myopathy. In one aspect of the invention, a combination is provided comprising an extracorporeal device (1) having contained therein a binding compound (11) bound to a carrier (9), the binding compound having affinity for a binding partner, and a plurality of affinity binders (15), each of said affinity binders comprising a first portion (19) comprising the binding partner and a second portion (17) adapted to bind selectively with a species, the second portions of each of said affinity binders differing from each other.
    Type: Application
    Filed: April 23, 2003
    Publication date: December 8, 2005
    Inventor: Meir Strahilevitz
  • Publication number: 20050265926
    Abstract: A treatment method comprising administration of visualization ligands or treatment ligands in a ligand-encapsulating vehicle, such as a liposome, preceded by administration of a “cold” vehicle, such as a liposome, lacking visualization ligands and treatment ligands. The cold vehicle accumulates in the reticulo-endothelial system of the mammal to which it is administered and minimizes the accumulation of the ligand-encapsulating vehicle carrying the visualization ligands or treatment ligands in the reticulo-endothelial system, thus reducing the toxicity of the ligands on the reticulo-endothelial system.
    Type: Application
    Filed: May 24, 2005
    Publication date: December 1, 2005
    Inventor: Meir Strahilevitz
  • Publication number: 20040220508
    Abstract: Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.
    Type: Application
    Filed: December 22, 2003
    Publication date: November 4, 2004
    Inventor: Meir Strahilevitz
  • Patent number: 6676622
    Abstract: Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: January 13, 2004
    Inventor: Meir Strahilevitz
  • Patent number: 6602502
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment of both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine.
    Type: Grant
    Filed: May 13, 1991
    Date of Patent: August 5, 2003
    Inventor: Meir Strahilevitz
  • Patent number: 6569112
    Abstract: Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: May 27, 2003
    Inventor: Meir Strahilevitz
  • Publication number: 20020019603
    Abstract: Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.
    Type: Application
    Filed: June 26, 2001
    Publication date: February 14, 2002
    Inventor: Meir Strahilevitz
  • Publication number: 20010039392
    Abstract: Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.
    Type: Application
    Filed: June 26, 2001
    Publication date: November 8, 2001
    Inventor: Meir Strahilevitz
  • Patent number: 6264623
    Abstract: Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.
    Type: Grant
    Filed: January 15, 1998
    Date of Patent: July 24, 2001
    Inventor: Meir Strahilevitz
  • Patent number: 6039946
    Abstract: Extracorporeal affinity adsorption devices which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man, provide effective therapeutic intervention means for these diseases. The devices are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for artherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.
    Type: Grant
    Filed: June 8, 1995
    Date of Patent: March 21, 2000
    Inventor: Meir Strahilevitz
  • Patent number: 5840588
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment or both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine, by active immunization and also passive immunization.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 24, 1998
    Inventor: Meir Strahilevitz
  • Patent number: 5753227
    Abstract: Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods are particularly suitable for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases. Extracorporeal chelation and immunotherapy for atherosclerosis, extracorporeal chelation treatment with on-line regeneration or replacement of chelant, extracorporeal immunotherapy with antibody fragments, and extracorporeal immunoadsorption utilizing antibodies bound to Protein A are also disclosed.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: May 19, 1998
    Inventor: Meir Strahilevitz
  • Patent number: 5677132
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment of both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine), by active immunization and also passive immunization.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: October 14, 1997
    Inventor: Meir Strahilevitz
  • Patent number: 5643732
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment or both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine by active immunization and also passive immunization.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 1, 1997
    Inventor: Meir Strahilevitz
  • Patent number: 5037645
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment of both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine, by active immunization and also passive immunization.
    Type: Grant
    Filed: May 1, 1989
    Date of Patent: August 6, 1991
    Inventor: Meir Strahilevitz
  • Patent number: 4834973
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment of both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine), by active immunization and also passive immunization.
    Type: Grant
    Filed: October 30, 1986
    Date of Patent: May 30, 1989
    Inventor: Meir Strahilevitz
  • Patent number: 4813924
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment of both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine), by active immunization and also passive immunization including immunodialysis and immunoadsorption treatment methods. Devices are disclosed for carrying out the immunodialysis and immunoadsorption methods.
    Type: Grant
    Filed: March 8, 1985
    Date of Patent: March 21, 1989
    Inventor: Meir Strahilevitz
  • Patent number: 4620977
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment of both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine, as treatments for drug dependence and for schizophrenia.
    Type: Grant
    Filed: November 9, 1981
    Date of Patent: November 4, 1986
    Inventor: Meir Strahilevitz
  • Patent number: 4375414
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment of both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine, by active immunization and also passive immunization including immunodialysis and immunoadsorption treatment methods. Devices are disclosed for carrying out the immunodialysis and immunoadsorption methods.
    Type: Grant
    Filed: January 21, 1977
    Date of Patent: March 1, 1983
    Inventor: Meir Strahilevitz